8-K: Vor Biopharma Announces Positive Clinical Data and FDA Feedback for Trem-cel Therapy in AML

Vor Biopharma reported updated clinical data showing improved relapse-free survival for AML patients treated with trem-cel followed by Mylotarg, along with supportive feedback from the FDA on their registrational trial design.

Summary

• Vor Biopharma has released updated clinical data from its Phase 1/2 VBP101 study, which involves patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg.
• The data, as of November 1, 2024, includes 25 patients treated with trem-cel, with 15 of those receiving Mylotarg.
• The study showed preliminary evidence of improved relapse-free survival, with a median RFS not reached after a median follow-up of 7.4 months, compared to published data on high-risk AML patients post-transplant.
• The treatment demonstrated shielding of the blood system, maintaining neutrophil and platelet counts across multiple Mylotarg doses.
• The therapeutic index for Mylotarg was broadened when administered after trem-cel.
• The study also showed reliable engraftment, with 100% of patients achieving primary neutrophil engraftment at a median of 9.5 days, robust platelet recovery at a median of 16 days, and full myeloid donor chimerism at Day 28.
• Trem-cel continues to be manufactured with high CD33 editing efficiency, with a median of 90% and a range of 71-94%.
• The company received supportive feedback from the FDA in a Type C meeting, aligning on the registrational clinical trial design for trem-cel and Mylotarg.

Sentiment

Score: 8

Explanation: The document presents very positive clinical data and supportive FDA feedback, indicating a strong potential for the company's therapy. The high engraftment rates, improved relapse-free survival, and broadened therapeutic index are all very encouraging. However, it is still early-stage data, and there are inherent risks in clinical development, which prevents a perfect score.

Positives

• The study shows promising early evidence of improved relapse-free survival in AML patients.
• Trem-cel effectively shields the blood system, allowing for the use of Mylotarg without significant toxicity.
• The broadened therapeutic index of Mylotarg after trem-cel treatment is a significant advantage.
• The high rate of engraftment and robust recovery of blood cell counts are positive indicators of treatment efficacy.
• The FDA's supportive feedback on the registrational trial design is a major step forward for the program.

Negatives

• The data is still preliminary, and longer follow-up is needed to confirm the long-term benefits.
• There were four relapses observed, although two of these were prior to Mylotarg treatment.
• Some patients experienced adverse events, including hematologic issues and elevated liver enzymes, although these were generally manageable.

Risks

• The study is still in Phase 1/2, and the results may not be replicated in larger, later-stage trials.
• Regulatory approvals are not guaranteed, and the FDA may require additional data or changes to the trial design.
• The company's manufacturing capabilities and efforts need to be successful to ensure a consistent supply of trem-cel.
• There are inherent risks in clinical trials, including the possibility of unexpected adverse events or lack of efficacy.
• The company's ability to continue as a going concern depends on securing sufficient funding for its operations.

Future Outlook

The company plans to provide further updates to the FDA alongside the submission of the full clinical trial protocol. They are also planning a registrational trial for trem-cel and Mylotarg.

Management Comments

• Dr. Eyal Attar, Vor Bio's Chief Medical Officer, stated that they are encouraged by the data and the potential of offering AML and MDS patients the opportunity to receive post-transplant maintenance therapy while maintaining healthy blood count levels.

Industry Context

This announcement is significant in the context of the broader cell and gene therapy field, particularly for blood cancers. The approach of using shielded transplants to enable targeted therapies post-transplant is innovative and could potentially address the high relapse rates seen in AML patients after hematopoietic stem cell transplants. The positive FDA feedback also positions Vor Biopharma well in the competitive landscape.

Comparison to Industry Standards

• The reported median relapse-free survival (RFS) for the VBP101 study is not reached with a median follow-up of 7.4 months, which appears favorable when compared to historical controls.
• Araki et al. (JCO 2016) reported a median PFS of 3.8 months in MRD+ AML patients post-transplant, while Jentzsch et al. (Blood Cancer Journal 2022) reported a median EFS of 6.2 months in adverse risk AML patients.
• The 100% engraftment rate and rapid neutrophil and platelet recovery observed in the VBP101 study are also notable, as these are critical factors for successful transplants.
• The ability to maintain neutrophil and platelet counts across multiple Mylotarg doses is a significant improvement over traditional Mylotarg treatment, which often results in severe myelosuppression.
• The high CD33 editing efficiency of trem-cel (median 90%) is also a key differentiator, as it ensures that the transplanted cells are effectively shielded from CD33-targeted therapies.

Stakeholder Impact

• Shareholders will likely view the positive clinical data and FDA feedback favorably.
• Patients with AML may benefit from this new treatment option, which could improve their relapse-free survival.
• Employees of Vor Biopharma will be encouraged by the progress of their clinical programs.
• The company's success could lead to increased demand for their products and services from healthcare providers.

Next Steps

• The company will provide further updates to the FDA alongside submission of the full clinical trial protocol.
• The company plans to initiate a registrational clinical trial for trem-cel and Mylotarg.

Key Dates

Keywords

Trem-cel, Mylotarg, AML, Relapse-Free Survival, Hematopoietic Stem Cell Transplant, FDA, Clinical Trial, Engraftment, CD33, Cell Therapy